Difference between revisions of "Caplacizumab (Cablivi)"
Jump to navigation
Jump to search
m |
|||
| Line 7: | Line 7: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 2/6/2019: Initial approval for adult patients with [[Thrombotic thrombocytopenic purpura|acquired thrombotic thrombocytopenic purpura (aTTP)]], in combination with plasma exchange and immunosuppressive therapy. | * 2/6/2019: Initial approval for adult patients with [[Thrombotic thrombocytopenic purpura|acquired thrombotic thrombocytopenic purpura (aTTP)]], in combination with plasma exchange and immunosuppressive therapy. | ||
| + | |||
| + | == Patient Drug Information== | ||
| + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761112s000lbl.pdf Caplacizumab (Cablivi) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761112s000lbl.pdf Caplacizumab (Cablivi) Package Insert]</ref> | ||
==Also known as== | ==Also known as== | ||
Revision as of 10:22, 4 April 2021
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Diseases for which it is used
History of changes in FDA indication
- 2/6/2019: Initial approval for adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Patient Drug Information
Also known as
- Code name: ALX-0081
- Generic name: caplacizumab-yhdp
- Brand name: Cablivi